Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Chronic rhinosinusitis (CRS) affects between 7% and 15.5% of the US population. In Europe, the latest estimates put prevalence at 10.9%.1 ,2 The condition produces symptoms such as nasal congestion, facial pressure/pain, purulent nasal drainage and is associated with significant fatigue and decreased productivity. While complications from the disease are rare, CRS is often treated with antibiotics, based on an older understanding that CRS results from bacterial infection. Newer data strongly suggest that CRS results from chronic inflammation of the sinonasal mucosa.3 Among otolaryngologists, the treatment strategy has shifted towards the use of antiinflammatory medications, such as topical and systemic corticosteroids. Choosing the optimal, …
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.